Breast cancer

Aggressive or slow-growing tumor? Contrast agent gives clues

A new magnetic resonance imaging (MRI) contrast agent being tested by researchers at Case Western Reserve University not only pinpoints breast cancers at early stages but differentiates between aggressive and slow-growing types.

“Doing both will help doctors find the right treatment,” said Zheng-Rong Lu, the M. Frank Rudy and Margaret Domiter Rudy Professor of Biomedical Engineering at Case Western Reserve and leader of the research. “There’s no such technology available now that we know of.”

Illustration of the concept of work. The targeted contrast agent, ZD2-Gd3N@C80,...
Illustration of the concept of work. The targeted contrast agent, ZD2-Gd3N@C80, binds to aggressive tumor and produces strong signal enhancement, but not in slow-growing tumors, which allow detection and risk-stratification of breast cancer.
Case Western Reserve University

The gadolinium-based agent is also more efficient and safer than traditional agents, requiring a gadolinium dose 20-times smaller, easily flushing from the body and leaving no accumulation in tissues, the researchers found in tests with mouse models. At the low dosage, the agent lights up cancer biomarkers during scans, overcoming the low sensitivity of MRI’s for imaging the markers. The research was published today (Sept. 25) in Nature Communications.

To make the agent, Lu and colleagues at Case Western Reserve combined commercially available tri-gadolinium nitride metallofullerene (Gd3N@C80), a highly efficient contrast agent, with a peptide labeled ZD2, which was developed in Lu’s lab.

Compared to the gadolinium used in traditional agents, Gd3N@C80’s “structure is different—the gadolinium ions are encaged in a hollow molecule of fullerene that looks like a soccer ball,” Lu said. “The cage prevents direct contact between the gadolinium and tissue, and the gadolinium will not be released, which prevents any kind of interaction with tissue. But the key technology for our targeted contrast agent is the peptide attached,” Lu said.

Photo
The figure shows the different expression of the biomarker (EDB-FN) and probe binding (ZD2) in slow-growing ER-positive breast cancer (not much yellow and red color representing low expression of the biomarker and low binding), and in triple- negative breast cancer (TNBC, high expression and high binding). As a result, the targeted contrast agent produced weak signal enhancement (brightness) in the former and strong signal (brightness) in the latter as pointed by the arrow. The technology is able to provide accurate detection and risk-stratification of aggressive BC.
Source: Case Western Reserve University

The lab applies ZD2 to the surface of the soccer ball. The peptide specifically targets the cancer protein extradomain-B fibronectin (EDB-FN). EDB-FN, which is associated with tumor invasion, metastasis and drug resistance, is highly expressed in the matrix around cancerous cells in many aggressive forms of human cancers.

In testing on six mouse models, MRI’s detected breast cancers in all cases. But the signal created by the accumulation of contrast molecules on three aggressive triple-negative breast cancers (MDA-MB-231, Hs578T and BT549) were significantly brighter. Because slow-moving ER-positive breast cancers (MCF-7, ZR-75-1 and T47D) produce less EDB-FN, fewer molecules attached. While detectible, the signal was muted.


Source: Case Western Reserve University

26.09.2017

Read all latest stories

Related articles

Photo

Tumor detection

MRI without contrast agents? Yes, with sugar!

Scientists from the German Cancer Research Center (DKFZ), in collaboration with colleagues from Heidelberg University Hospital, have been able to visualize brain cancer using a novel MRI method. They…

Photo

The search is on

MRI contrast agents: Aiming to work without radioactivity

MRI is now indispensable for diagnosing diseases and monitoring therapies. However, the ongoing discussion on gadolinium deposits in the brain has intensified the search for alternatives. Dr Daniel…

Photo

Contrast agent in cola drinks

Gadolinium found in fast food restaurants

It has been found in many rivers and even in the tap water in some German cities, now scientists detected gadolinium from contrast agents in the food chain. A research group headed by Michael Bau,…

Related products

allMRI GmbH – MRI vacuum immobilisation for head coils

Accessories / Complementary systems

allMRI GmbH – MRI vacuum immobilisation for head coils

allMRI GmbH
allMRI GmbH – MRI wheelchair – foldable

Accessories / Complementary systems

allMRI GmbH – MRI wheelchair – foldable

allMRI GmbH
allMRI GmbH – MRI wheeled waste bin – 90 liters

Accessories / Complementary Systems

allMRI GmbH – MRI wheeled waste bin – 90 liters

allMRI GmbH
Block Imaging

3 Tesla

Block Imaging

Block Imaging
Canon – Vantage Elan

1.5 Tesla

Canon – Vantage Elan

Canon Medical Systems Europe B.V.
Canon – Vantage Galan 3 T

3 Tesla

Canon – Vantage Galan 3 T

Canon Medical Systems Europe B.V.